|
|
News
CryoCath Appoints Vice President, Europe
Montreal, Canada, July 2, 2008 - CryoCath Technologies Inc. (TSX: CYT), the global leader in cryotherapy products
to treat cardiac arrhythmias, today announced the appointment of Frank
Vandeputte as Vice President, Europe. Based in CryoCath’s new European
headquarters in Leiden, The Netherlands, Mr. Vandeputte will be responsible for
leading the European business operation. This includes the development and
implementation of strategic and operational business plans, with the objective
of driving ongoing rapid sales growth of the Company’s innovative products in
the European market.
Mr. Vandeputte joins CryoCath with more than 20
years of experience in the medical device industry. Most recently, he served as
Area Vice President Benelux and Nordic for the Sorin Group, based in Brussels.
Prior to that he was Vice President International Marketing with the Sorin
Group. Prior to Sorin, he held senior management positions with leading medical
device companies, including Baxter International Inc, Becton Dickinson and
Guidant Corporation. With Guidant, he has been providing leadership to their
European Cardiac Resynchronisation Therapy, Endovascular and Cardiac Surgery
business, and served as Country Manager for Germany as well.
“With his
proven leadership and medical device industry successes, Frank will be an asset
to our European commercial operations. He, and his successful European
leadership team, will spearhead the ongoing rapid growth of Arctic Front in
Europe,” said Jan Keltjens, CryoCath President and CEO. “Additionally, we have
now opened our European headquarters in Leiden, the Netherlands. This will allow
us to better serve the needs of our expanding customer base in Europe. By
establishing a strong European presence and enhancing our management team, we
are continuing to execute on our strategy of becoming a leader in atrial
fibrillation therapy.”
About Medtronic CryoCathCryoCath – www.cryocath.com – is a medical technology company that leads the
world in cryotherapy products to treat cardiac arrhythmias. With a priority
focus on providing physicians with a complete solution of catheter products to
treat cardiac arrhythmias, CryoCath has multiple products approved in the U.S.,
across Europe and several ROW countries. The Company is developing additional
products to expand its pipeline of products to treat cardiac
arrhythmias.
This press release includes “forward looking statements”
that are subject to risks and uncertainties, including with respect to the
timing of regulatory trials and their outcome. For information identifying
legislative or regulatory, economic, currency, technological, competitive and
other important factors that could cause actual results to differ materially
from those anticipated in the forward looking statements, see CryoCath’s annual
report available at www.sedar.com under the heading Risks and Uncertainties in
the Management’s Discussion and Analysis section.
For further information, please contact:
|
|
